

# Xbrane Biopharma changes the date for Interim and Year-end Report

**Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) announces today change of date for the Interim Report for the fourth quarter 2021 as well as the 2021 Year-end Report, to February 24, 2022, from previously communicated February 16, 2022.**

The Company hereby also invites to a phone conference for investors, analysts, and media on Thursday 24 February 2022 at 10:00 am CET when the Interim report will be presented.

## Contacts

---

Martin Åmark, CEO  
M: +46 76 309 37 77  
E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR  
M: +46 76 325 60 90  
E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

## About Us

---

*Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.3bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally four biosimilar candidates in its pipeline targeting € 24.3bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.*

*For more information, visit [www.xbrane.com](http://www.xbrane.com).*

## Attachments

---

[Xbrane Biopharma changes the date for Interim and Year-end Report](#)